Repetitive transcranial magnetic stimulation (rTMS)Mirror therapy using virtual realityMirror therapy using sham mirror
Repetitive transcranial magnetic stimulation (rTMS): 20 minutes of high frequency (20Hz) rTMS.
Mirror therapy using virtual reality: active mirror-based therapy
Mirror therapy using sham mirror: 20 minutes of sham mirror-based therapy
Study summary
Neuropathic pain is particularly difficult to treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their analgesic effect.Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rTMS.The present project will investigate in individuals with neuropathic pain the effects of the rTMS coupled with virtual reality mirror therapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
* Clinical symptoms typical of neuropathic pain
* Refractory to drug therapies
* Lasting for at least 6 months, with a moderate to severe pain intensity (≥4/10 on Visual Analog Scale, VAS) and a stable pain treatment since 1month at least
* Having right to health benefits
Exclusion Criteria:
* Ferromagnetic components and implanted microprocessors (i.e. cochlear implants)
* Drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or personality troubles, and ongoing opioid treatment.
* Any other contraindications to MRI scanner (e.g., claustrophobia, etc.).
Primary outcome measure(s)
Pain intensity measurement — Week 9 Averages of the daily visual analogue scale scores (min no pain max pain imaginable) measured during the first week (Week 1) and that measured during the week following the last session (week 9)
Trial sites (2)
Facility
City
Region
Status
Hôpital Neurologique Pierre Wertheimer
Bron
France
Not Yet Recruiting
Centre Hospitalier Universitaire de Saint-Etienne
Saint-Etienne
France
Recruiting
More Centre Hospitalier Universitaire de Saint Etienne trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.